Pascal Deschatelets is Chief Scientific Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 1.15 Million shares of APLS, which is worth approximately $33.8 Million. The most recent transaction as insider was on Mar 10, 2021, when has been sold 6,250 shares (Common Stock) at a price of $50.74 per share, resulting in proceeds of $317,125. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.15M
0.63% 3M change
2.74% 12M change
Total Value Held $33.8 Million

Pascal Deschatelets Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 10 2021
SELL
Open market or private sale
$317,125 $50.74 p/Share
6,250 Reduced 0.72%
865,087 Common Stock
Mar 10 2021
BUY
Exercise of conversion of derivative security
$16,688 $2.67 p/Share
6,250 Added 0.71%
871,337 Common Stock
Feb 10 2021
SELL
Payment of exercise price or tax liability
$32,831 $47.72 p/Share
688 Reduced 0.08%
865,087 Common Stock
Jan 28 2021
BUY
Grant, award, or other acquisition
-
9,375 Added 1.07%
865,775 Common Stock
PD

Pascal Deschatelets

Chief Scientific Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS